Trial Search Results
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Stanford is currently not accepting patients for this trial.
- Drug: 89Zr-panitumumab
- Confirmed diagnosis of pancreatic cancer.
- Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive
heart failure (CHF); significant liver disease; or unstable angina within 6 months
prior to enrollment.
- History of infusion reactions to monoclonal antibody therapies.
- Pregnant or breastfeeding.
- Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,
amiodarone, sotalol) antiarrhythmic agents.
- Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
- Severe renal disease or anuria.
- Known hypersensitivity to deferoxamine or any of its components.
Ages Eligible for Study
19 Years - N/A
Genders Eligible for Study